BRPI0921640A2 - agonistas peptídicos do crhr2 e usos do mesmo - Google Patents

agonistas peptídicos do crhr2 e usos do mesmo

Info

Publication number
BRPI0921640A2
BRPI0921640A2 BRPI0921640A BRPI0921640A BRPI0921640A2 BR PI0921640 A2 BRPI0921640 A2 BR PI0921640A2 BR PI0921640 A BRPI0921640 A BR PI0921640A BR PI0921640 A BRPI0921640 A BR PI0921640A BR PI0921640 A2 BRPI0921640 A2 BR PI0921640A2
Authority
BR
Brazil
Prior art keywords
peptide agonists
crhr2 peptide
crhr2
agonists
peptide
Prior art date
Application number
BRPI0921640A
Other languages
English (en)
Inventor
P Shankley Nigel
Gengo Peter
V Swanson Ronald
Moreno Veronica
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0921640A2 publication Critical patent/BRPI0921640A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
BRPI0921640A 2008-11-04 2009-11-04 agonistas peptídicos do crhr2 e usos do mesmo BRPI0921640A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11123308P 2008-11-04 2008-11-04
US17889009P 2009-05-15 2009-05-15
PCT/US2009/063276 WO2010053990A2 (en) 2008-11-04 2009-11-04 Crhr2 peptide agonists and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0921640A2 true BRPI0921640A2 (pt) 2019-09-24

Family

ID=41509080

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921640A BRPI0921640A2 (pt) 2008-11-04 2009-11-04 agonistas peptídicos do crhr2 e usos do mesmo

Country Status (20)

Country Link
US (1) US10040838B2 (pt)
EP (1) EP2362881B1 (pt)
JP (1) JP2012508014A (pt)
KR (1) KR20110091720A (pt)
CN (1) CN102272151B (pt)
AU (1) AU2009313619A1 (pt)
BR (1) BRPI0921640A2 (pt)
CA (1) CA2742710A1 (pt)
CO (1) CO6341479A2 (pt)
CR (1) CR20110305A (pt)
EA (1) EA201170647A1 (pt)
EC (1) ECSP11011099A (pt)
ES (1) ES2723098T3 (pt)
IL (1) IL212685A0 (pt)
MX (1) MX2011004718A (pt)
NI (1) NI201100087A (pt)
NZ (1) NZ592670A (pt)
SG (1) SG171957A1 (pt)
WO (1) WO2010053990A2 (pt)
ZA (1) ZA201104160B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0921640A2 (pt) 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
KR20120103606A (ko) * 2009-11-04 2012-09-19 얀센 파마슈티카 엔.브이. 스트레스코핀-유사 펩타이드를 이용해 심부전을 치료하는 방법
JP6562632B2 (ja) * 2012-02-14 2019-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
IL328216A (en) * 2023-11-17 2026-07-01 Lilly Co Eli Compounds for the treatment of diabetes or obesity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG88714A1 (en) 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
AU1674292A (en) * 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
RU2305109C2 (ru) * 2001-03-15 2007-08-27 Рисерч Дивелопмент Фаундейшн Урокортин iii, его аналог (варианты) и фармацевтическая композиция
DK1389137T3 (da) 2001-05-21 2006-10-30 Injet Digital Aerosols Ltd Sammensætninger til lungelægemiddellevering af protein
AU2002351214B2 (en) * 2001-12-03 2008-09-11 Metabolex, Inc. Methods and reagents for diagnosis and treatment of diabetes
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
CN100480267C (zh) * 2002-01-16 2009-04-22 宝洁公司 促肾上腺皮质激素释放因子2受体激动剂
KR100512483B1 (ko) * 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP1675620B1 (en) * 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
CA2575101A1 (en) * 2004-06-12 2005-12-29 Bayer Pharmaceuticals Corporation Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
PA8660701A1 (es) * 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007090087A2 (en) 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JP2010527989A (ja) 2007-05-25 2010-08-19 ネウトロン リミテッド 半減期が延長されたｃｒｆ複合体
AU2008303893A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
CA2699066A1 (en) 2007-09-14 2009-03-19 Basf Plant Science Gmbh Plants having increased yield-related traits and a method for making the same comprising expression of a growth-regulating factor (grf) polypeptide
BRPI0921640A2 (pt) 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
WO2011041897A1 (en) 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
KR20120103606A (ko) * 2009-11-04 2012-09-19 얀센 파마슈티카 엔.브이. 스트레스코핀-유사 펩타이드를 이용해 심부전을 치료하는 방법
HUE053664T2 (hu) 2011-07-18 2021-07-28 The United States Of America Eljárások és készítmények Polyomavírussal összefüggõ betegségek gátlására

Also Published As

Publication number Publication date
JP2012508014A (ja) 2012-04-05
NZ592670A (en) 2013-01-25
US20100130424A1 (en) 2010-05-27
US10040838B2 (en) 2018-08-07
CN102272151B (zh) 2014-08-20
SG171957A1 (en) 2011-07-28
AU2009313619A1 (en) 2010-05-14
CN102272151A (zh) 2011-12-07
ES2723098T3 (es) 2019-08-21
WO2010053990A3 (en) 2010-07-01
CO6341479A2 (es) 2011-11-21
MX2011004718A (es) 2011-07-28
EP2362881B1 (en) 2019-03-13
EP2362881A2 (en) 2011-09-07
ECSP11011099A (es) 2011-07-29
ZA201104160B (en) 2012-11-28
KR20110091720A (ko) 2011-08-12
CA2742710A1 (en) 2010-05-14
IL212685A0 (en) 2011-07-31
NI201100087A (es) 2011-10-25
EA201170647A1 (ru) 2011-12-30
CR20110305A (es) 2011-11-10
WO2010053990A2 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
HRP20190137T1 (hr) Stabilne formulacije polipeptida i njihova uporaba
BRPI0719732A2 (pt) nanopartículas de peptídeo e usos para as mesmas
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
NL300891I2 (nl) Lotilaner en zouten daarvan
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
IL238669A0 (en) Extended soluble ph20 polypeptides and uses thereof
HRP20170698T1 (hr) Lizosomski usmjereni peptidi i njihove uporabe
DK2349430T3 (da) KATETERISERINGANORDNING og -kit
BR112012013148A2 (pt) formulação farmacêutica e uso
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
BRPI0921822A2 (pt) composição compreendendo polímero e enzima
DK2272339T3 (da) Fremgangsmåder og præparater til anvendelse med geldispensere
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0922486A2 (pt) microcápsulas e suas respectivas utilizações
HRP20160579T1 (hr) Spoj indola i njegova farmaceutska upotreba
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
BR112012006501A2 (pt) polipeptídios e usos dos mesmos
PT2356462T (pt) Composições e métodos anti-cxcr1
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
BRPI0918328A2 (pt) composição e artigo
BRPI0913807A2 (pt) composição e artigo
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.